Test ADI-PEG 20 versus placebo for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests whether ADI-PEG 20 helps people with advanced, unresectable hepatocellular carcinoma (liver cancer) who have high arginine levels. Participants get ADI-PEG 20 or a placebo to see which works better and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (HCC) confirmed by scan or lab (biopsy/cell testing).
- Your cancer cannot be fully removed by surgery and is classified as BCLC stage C.
- Your blood arginine level is high enough (at least 78 μM) before starting.
- You have at least one measurable tumor spot on a scan, and any prior local treatment is finished at least 4 weeks before the baseline CT.
- You are living with cirrhosis that fits in range A to B7 (not worse), and you’re expected to live at least 3 months.
- Your daily functioning is fairly good (ECOG 0–1), and key blood tests show enough liver function and blood counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, ADI-PEG 20 and Lenvatinib, for people with advanced liver cancer that cannot be removed by surgery. It aims to see if this combination can help shrink or control the cancer.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.